MicroPort Scientific Corporation Unveils Groundbreaking TARGET-FIRST Clinical Trial Results for Firehawk® Stents, Reducing Dual Antiplatelet Therapy to One Month with 54% Decrease in Bleeding Complications
Reuters
Sep 01
MicroPort Scientific Corporation Unveils Groundbreaking TARGET-FIRST Clinical Trial Results for Firehawk® Stents, Reducing Dual Antiplatelet Therapy to One Month with 54% Decrease in Bleeding Complications
MicroPort Scientific Corporation has announced the publication of results from the TARGET-FIRST clinical trial in the New England Journal of Medicine. The study focused on the Firehawk® Drug Eluting Stent System, independently developed by the company. The results, which were also presented at the European Society of Cardiology Congress 2025 in Spain, indicate that for patients suffering from low-risk acute myocardial infarction who undergo complete revascularization with Firehawk® Stents, the duration of dual antiplatelet therapy can be reduced from 12 months to one month. This reduction does not increase ischaemic risks and significantly lowers bleeding complications. Firehawk® Stents have been introduced in 67 countries across Asia, Europe, the Americas, Africa, and Oceania, and the company aims to focus on commercialization and promotion in North America.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MicroPort Scientific Corporation published the original content used to generate this news brief on September 01, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.